Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Natural and Synthetic Exogenous Surfactants in the Management of Neonatal Respiratory Distress Syndrome

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Alveolar surfactant is central to pulmonary physiology. Quantitative and qualitative surfactant abnormalities appear to be the primary aetiological factors in neonatal respiratory distress syndrome (RDS) and exogenous replacement of surfactant is a rational treatment. Available exogenous surfactants have a natural (mammal-derived lung surfactants) or synthetic origin.

Pharmacodynamic and clinical studies have demonstrated that exogenous surfactants immediately improve pulmonary distensibility and gas exchange; however, this is achieved more slowly and with more failures with synthetic surfactants. The ensuing advantageous haemodynamic effects are not so striking and they include an inconvenient increased left to right ductal shunt.

Two strategies of administration have been used: prophylactic or rescue therapy to treat declared RDS. All methods of instillation require intubation. In addition to the early benefits (improved gas exchange and reduced ventilatory support) the incidence of classical complications of RDS, especially air leak events, is decreased except for the uncommon problem of pulmonary haemorrhage. The incidence of bronchopulmonary dysplasia is neither uniformly nor significantly reduced although the severity appears to be lessened. The overall incidence of peri-intraventricular haemorrhages is not diminished although separate trials have shown a decreased rate. The most striking beneficial effect of exogenous surfactants is the increased survival (of about 40%) of treated very low birthweight neonates. A small number of adverse effects has been described.

The long term outcome of survivor neonates with RDS treated with surfactants versus control neonates with RDS not treated with surfactants is similar in terms of physical growth, at least as good in terms of respiratory status, with a similar or slightly better neurodevelopmental outcome. There is no clear benefit of exogenous surfactant therapy in extremely premature infants (<26 weeks gestational age, birthweight <750g).

The potential risks of contamination, inflammatory and immunogenic reaction and the inhalation of platelet activating factor remain a theoretical concern of surfactant therapy which has not been confirmed in clinical practice. The optimal timing of treatment favours prophylaxis over rescue treatment and early rescue treatment rather than delayed therapy. Meta-analyses suggest the clinical superiority of natural surfactant extracts over a synthetic one (colfosceril palmitate). The economic impact of surfactant therapy is favourable and the costs per quality-adjusted life year (QALY) for surviving surfactant treated infants are low.

In conclusion, the mid and long term benefit/risk ratio clearly favours the use of exogenous surfactants to prevent or to treat RDS in neonates who have a gestational age of >26 weeks or a birthweight of >750g, especially with the prophylactic strategy using natural surfactant extracts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bourbon JR. Pulmonary surfactant: biochemical, regulatory, and clinical concepts. Boca Raton, FL: CRC Press, 1991

    Google Scholar 

  2. Dehan M, Francoual J, Imbert MC, et al. Etiology of neonatal respiratory distress syndrome and the assessment of lung maturity. In: Bourbon JR, editor. Pulmonary surfactant: biochemical, functional, regulatory and clinical concept. Boston, MA: CRC Press, 1991: 336–56

    Google Scholar 

  3. Fujiwara T, Chida S, Watabe Y, et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980: I: 55–9

    Article  Google Scholar 

  4. Collaborative European Multicentre Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1988: 82: 683–91

    Google Scholar 

  5. Liechty E, Donovan E, Puhorit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 1991: 88: 19–28

    PubMed  CAS  Google Scholar 

  6. Long W, Corbet A, Cotton R, et al. A controlled trial of synthetic surfactant in infants weighing 1250g or more with respiratory distress syndrome. N Engl J Med 1991: 325: 1696–703

    Article  PubMed  CAS  Google Scholar 

  7. Merritt TA, Hallman M, Berry C, et al. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr 1991: 118: 581–94

    Article  PubMed  CAS  Google Scholar 

  8. Ten Centre Study Group. Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. BMJ 1987: 294: 991–6

    Article  Google Scholar 

  9. Enhörning G, Shennan A, Possmayer F, et al. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: arandomized clinical trial. Pediatrics 1985: 76: 145–53

    PubMed  Google Scholar 

  10. Fujiwara T, Konishi M, Chida S, et al. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome. Final analysis of a multicentre, double-blind, randomized trial and comparison with similar trials. Pediatrics 1990: 86: 753–64

    PubMed  CAS  Google Scholar 

  11. Fujiwara T, Robertson B. Pharmacology of exogenous surfactant. In: Robertson B, Van Golde IMG, Batenburg JJ, editors. Pulmonary surfactant: from molecular biology to clinical practice. Amsterdam: Elsevier Science, 1992: 561–92

    Google Scholar 

  12. Seeger W, Grube C, Günther A, et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993: 6: 971–7

    PubMed  CAS  Google Scholar 

  13. Halliday H. Overview of clinical trials comparing natural and synthetic surfactants. Biol Neonate 1995: 67 Suppl. 1: 32–47

    PubMed  Google Scholar 

  14. Cotton RB, Olsson T, Law AB, et al. The physiologic effects of surfactant treatment on gas exchange in newborn premature infants with hyaline membrane disease. Pediatr Res 1993: 34: 495–501

    Article  PubMed  CAS  Google Scholar 

  15. Edberg K, Ekström-Jodal B, Hallman M, et al. Immediate effects on lung function of instilled human surfactant in mechanically ventilated newborn infants with IRDS. Acta Paediatr Scand 1990: 79: 750–5

    Article  PubMed  CAS  Google Scholar 

  16. Goldsmith L, Greenspan J, Rubenstein S, et al. Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increase distension. J Pediatr 1991; 119: 424–8

    Article  PubMed  CAS  Google Scholar 

  17. Svenningsen N, Björklund L, Vilstrup C, et al. Lung mechanics (FRC and static pressure-volume diagram) after endotracheal surfactant instillation: preliminary observations. Biol Neonate 1992; 61: 44–7

    Article  PubMed  Google Scholar 

  18. Cotton R. A model of the effect of surfactant treatment on gas exchange in hyaline membrane disease. Sem Perinatol 1994; 18: 19–22

    CAS  Google Scholar 

  19. Baraldi E, Pettenazzo A, Filippone M, et al. Rapid improvement of static compliance after surfactant treatment in preterm infants with respiratory distress syndrome. Pediatr Pulmonol 1993; 15: 157–62

    Article  PubMed  CAS  Google Scholar 

  20. Choukroun M, Llanas B, Apere H, et al. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations. Pediatr Pulmonol 1994; 18: 273–8

    Article  PubMed  CAS  Google Scholar 

  21. Pfenninger J, Aebi C, Bachmann D, et al. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (EXOSURF). Pediatr Pulmonol 1992; 14: 10–5

    Article  PubMed  CAS  Google Scholar 

  22. Hudak M, Farrell E, Rosenberg A, et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996; 128: 396–406

    Article  PubMed  CAS  Google Scholar 

  23. Hörbar J, Wright L, Soll R, et al. A multicentre randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993; 123: 757–66

    Article  PubMed  Google Scholar 

  24. Cummings J, Holm B, Hudak M, et al. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis 1992; 145: 999–1004

    Article  PubMed  CAS  Google Scholar 

  25. Ikegami M, Ueda T, Absolom D, et al. Changes in exogenous surfactant in ventilated preterm lamb lung. Am Rev Respir Dis 1993; 148: 837–44

    Article  PubMed  CAS  Google Scholar 

  26. Fujiwara T, Konishi M, Chida S, et al. Factors affecting the response to a postnatal single dose of a reconstituted bovine surfactant (surfactant TA). In: Lachmann B, editor. Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Berlin: Springer-Verlag, 1988: 91–107

    Google Scholar 

  27. Charon A, Rauesch H, Fitzgibbon C, et al. Factors associated with surfactant response in infants with severe respiratory distress syndrome. Pediatrics 1989; 83: 348–54

    PubMed  CAS  Google Scholar 

  28. Segerer H, Stevens P, Schadow B, et al. Surfactant substitution in ventilated very low birth weight infants: factors related to response types. Pediatr Res 1991; 30: 591–6

    Article  PubMed  CAS  Google Scholar 

  29. Collaborative European Multicentre Study Group. Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Eur J Pediatr 1991; 150: 433–9

    Article  Google Scholar 

  30. Hamvas A, Devine T, Sessions Cole F. Surfactant therapy failure identifies infants at risk for pulmonary mortality. Am J Dis Child 1993; 147: 665–8

    PubMed  CAS  Google Scholar 

  31. Kuint J, Reichman B, Neumann L, et al. Prognostic value of the immediate response to surfactant. Arch Dis Child 1994; 71: F170–3

    Article  CAS  Google Scholar 

  32. Kääpä P, Seppänen M, Kero P, et al. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 1993; 123: 115–9

    Article  PubMed  Google Scholar 

  33. Hamden A, Shaw N. Changes in pulmonary arterial pressure in infants with respiratory distress syndrome. Arch Dis Child 1995; 72: F176–9

    Google Scholar 

  34. Halliday H, McCord F, McClure B, et al. Acute effects of surfactant in severe respiratory distress syndrome. Arch Dis Child 1989; 64: 13–6

    Article  PubMed  CAS  Google Scholar 

  35. Salidba E, Nashashibi M, Vaillant M, et al. Instillation rate effects of Exosurf on cerebral and cardiovascular haemodynam-ics in preterm neonates. Arch Dis Child 1994; 71: F174–8

    Google Scholar 

  36. Seppänen M, Kaapa P, Kero P. Acute effects of synthetic surfactant replacement on pulmonary blood flow in neonatal respiratory distress syndrome. Am J Perinatol 1994; 6: 382–5

    Article  Google Scholar 

  37. Jorch G, Rabe H, Garbe M, et al. Acute and protracted effects of intratracheal surfactant application on internal carotid blood flow velocity, blood pressure and carbon dioxide tension in very low birth weight infants. Eur J Pediatr 1989; 148: 770–3

    Article  PubMed  CAS  Google Scholar 

  38. Covan F, Whitelaw A, Wertheim D, et al. Cerebral blood flow velocity changes after rapid administration of surfactant. Arch Dis Child 1991; 66: 1105–9

    Article  Google Scholar 

  39. Van de Bor M, Ma E, Walther F. Cerebral blood flow velocity after Surfactant instillation in preterm infants. J Pediatr 1991; 118: 285–7

    Article  PubMed  Google Scholar 

  40. Van Bel F, De Winter PJ, Wijnands HGB, et al. Cerebral and aortic blood flow velocity patterns in preterm infants receiving prophylactic surfactant treatment. Acta Paediatr 1992; 81: 504–10

    Article  PubMed  Google Scholar 

  41. Skov L, Bell A, Greisen G. Surfactant administration and the cerebral circulation. Biol Neonate 1992; 61: 31–6

    Article  PubMed  Google Scholar 

  42. Skov L, Hellström-Westas L, Jacobsen T, et al. Acute changes in cerebral oxygenation and cerebral blood volume in preterm infants during surfactant treatment. Neuropediatrics 1992; 23: 126–30

    Article  PubMed  CAS  Google Scholar 

  43. Edwards A, McCornick D, Roth S, et al. Cerebral hemodynamic effects of treatment with modified natural surfactant investigated by near infrared spectroscopy. Pediatr Res 1992; 32: 532–6

    Article  PubMed  CAS  Google Scholar 

  44. Bell A, Skov L, Lundström K, et al. Cerebral blood flow and plasma hypoxanthine in relation to surfactant treatment. Acta Paediatr 1994; 83: 910–4

    Article  PubMed  CAS  Google Scholar 

  45. Rey M, Segerer H, Kiessling C, et al. Surfactant bolus instillation: effects of different doses on blood pressure and cerebral blood flow velocities. Biol Neonate 1994; 66: 16–21

    Article  PubMed  CAS  Google Scholar 

  46. Hellström-Westas L, Bell A, Skov L, et al. Cerebroelectrical depression following surfactant treatment in preterm neonates. Pediatrics 1992; 89: 643–7

    PubMed  Google Scholar 

  47. Hallahakoon C, Bell A, Young I, et al. Antioxidant status and EEG activity after exosurf administration [abstract]. Biol Neonate 1995; 67 Suppl. 1: 91

    Google Scholar 

  48. Lundstrom K, Greisen G. Changes in EEG, systemic circulation and blood gas parameters following two or six aliquots of porcine surfactant. Acta Paediatr 1996; 85: 708–12

    Article  PubMed  CAS  Google Scholar 

  49. Segerer H, Van Gelder W, Angement F, et al. Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique. Pediatr Res 1993; 34: 490–4

    Article  PubMed  CAS  Google Scholar 

  50. Zola E, Gunkel J, Chan R, et al. Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr 1993; 122: 453–9

    Article  PubMed  CAS  Google Scholar 

  51. Valls-i-Soler A, Lopez-Heredia J, Fernandez-Ruanova M, et al. A simplified surfactant dosing procedure in respiratory distress syndrome: the ’side-hole’ randomized study. Acta Paediatr 1997; 86: 747–51

    Article  PubMed  CAS  Google Scholar 

  52. Dechant K, Faulds D. Colfosceril palmitate: a review of therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (exosurf neonatal) in neonatal respiratory distress syndrome. Drugs 1991; 42: 877–94

    Article  PubMed  CAS  Google Scholar 

  53. Soll R. Clinical trials of surfactant therapy in the newborn. In: Robertson B, Taeusch H, editors. Surfactant therapy for lung disease. New York: Marcel Dekker, 1995: 407–41

    Google Scholar 

  54. Raju T, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr 1993: 123: 603–10

    Article  PubMed  CAS  Google Scholar 

  55. Garland J, Buck R, Weinberg M. Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study. Pediatrics 1994: 94: 719–23

    PubMed  CAS  Google Scholar 

  56. Pappin A, Shenker N, Hack M, et al. Extensive intraalveolar pulmonary hemorrhage in infants dying after surfactant therapy. J Pediatr 1994: 124: 621–6

    Article  PubMed  CAS  Google Scholar 

  57. Findlay R, Taeusch H, David-Cu R, et al. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactant. Pediatr Res 1995: 37: 26–30

    Article  PubMed  CAS  Google Scholar 

  58. Wilkinson A, Jenkins P, Jeffrey J. Two controlled trials of dry artificial surfactant: early effects and latter outcome in babies with surfactant deficiency. Lancet 1985: II: 287–91

    Article  Google Scholar 

  59. Long W, Thompson T, Sundell H, et al. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700–1350-gram infants with respiratory distress syndrome. J Pediatr 1991: 118: 595–605

    Article  PubMed  CAS  Google Scholar 

  60. Egberts J, De Winter J. Meta-analyses of surfactant and bronchopulmonary dysplasia revisited. Lancet 1994: 344: 882

    Article  PubMed  CAS  Google Scholar 

  61. Alpan G, Clyman R. Cardiovascular effects of surfactant replacement with special reference to the patent ductus arteriosus. In: Robertson B, Taeusch H, editors. Surfactant therapy for lung disease. New York: Marcel Dekker, 1995: 531–45

    Google Scholar 

  62. Hörbar J, Soll R, Schachinger H, et al. A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome. Eur J Pediatr 1990: 149: 416–23

    Article  PubMed  Google Scholar 

  63. Gunkel J, Banks P. Surfactant therapy and intracranial hemorrhage: review of the literature and results of new analyses. Pediatrics 1993: 92: 775–86

    PubMed  CAS  Google Scholar 

  64. Morley C, Greenough A, Miller N, et al. Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestation. Early Hum Dev 1988: 17: 41–54

    Article  PubMed  CAS  Google Scholar 

  65. Wegman M. Annual summary of vital statistics — 1991. Pediatrics 1992: 90: 835–45

    PubMed  CAS  Google Scholar 

  66. Halliday HL, Tarnow-Mordi WO, Corcoran JD, et al. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 1993: 69: 276–80

    Article  PubMed  CAS  Google Scholar 

  67. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant — the judgement of OSIRIS. 1992: 340: 1363–9

    Google Scholar 

  68. Casiro O, Bingham W, MacMurray B, et al. One-year follow-up of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome and randomized to two rescue doses of synthetic surfactant or air placebo. J Pediatr 1995: 126 Suppl.: S53–60

    Article  PubMed  CAS  Google Scholar 

  69. Termote J, Schalij-Delfos N, Cats B, et al. Less severe retinopathy of prematurity induced by surfactant replacement therapy. Acta Paediatr 1996: 85: 1491–6

    Article  PubMed  CAS  Google Scholar 

  70. Soll R, Hoekstra R, Fangman J, et al. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Pediatrics 1990: 85: 1092–102

    PubMed  CAS  Google Scholar 

  71. Ware J, Taeusch H, Soil R, et al. Health and developmental outcomes of a surfactant controlled trial: follow-up at 2 years. Pediatrics 1990: 85: 1103–7

    PubMed  CAS  Google Scholar 

  72. Morley C, Morley R. Follow-up of premature babies treated with artificial surfactant (ALEC). Arch Dis Child 1990: 65: 667–9

    Article  PubMed  CAS  Google Scholar 

  73. Robertson B, Curstedt T, Tubman R, et al. A 2-year follow-up of babies enrolled in a European multicenter trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Eur J Pediatr 1992: 151: 372–6

    Article  PubMed  CAS  Google Scholar 

  74. Vaucher Y, Harker L, Merritt TA, et al. Outcome of twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized placebo-controlled trial of human surfactant. J Pediatr 1993: 122: 126–32

    Article  PubMed  CAS  Google Scholar 

  75. Survanta Multicenter Study Group. Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. J Pediatr 1994: 124: 962–7

    Article  Google Scholar 

  76. Long W, Zucker J, Kraybill E. Symposium on synthetic surfactant II: health and developmental outcomes at one year. J Pediatr 1995: 126 Suppl.: S1–102

    Article  PubMed  CAS  Google Scholar 

  77. Yuksel B, Greenough A, Gamsu H. Respiratory function at follow-up after neonatal surfactant replacement therapy. Respir Med 1993: 87: 217–21

    Article  PubMed  CAS  Google Scholar 

  78. Abassi S, Bhutani V, Gerdes J. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J Pediatr 1993: 122: 446–2

    Article  Google Scholar 

  79. Couser R, Ferrara T, Wheeler W, et al. Pulmonary follow-up 2.5 years after a randomized, controlled, multiple dose bovine surfactant study of preterm newborn infants. Pediatr Pulmonol 1993: 15: 163–7

    Article  PubMed  CAS  Google Scholar 

  80. Walti H, Boulé M, Moriette G, et al. Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant at birth. Biol Neonate 1992: 61 Suppl. 1: 48–53

    PubMed  Google Scholar 

  81. Wagner C, Kramer B, Kendig J, et al. Neurodevelopmental and pulmonary outcome of 40 premature infants at 5–7 years: surfactant vs saline at birth [abstract]. Pediatr Res 1992: 31: 263A

    Google Scholar 

  82. Stevenson D, Walther F, Long W, et al. Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. J Pediatr 1992: 120 Suppl.: S3–12

    Article  PubMed  CAS  Google Scholar 

  83. Smyth J, Allen A, McMurray B, et al. Double-blind, randomized placebo-controlled Canadian multicenter trial of two doses of synthetic surfactant or air placebo in 224 infants weighing 500 to 749 grams with respiratory distress syndrome. J Pediatr 1995: 126 Suppl.: S81–5

    Article  PubMed  CAS  Google Scholar 

  84. Walther F, Mullet M, Schumacher R, et al. One-year follow-up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo at birth: results of a double blind study. J Pediatr 1995: 126 Suppl.: S13–9

    Article  PubMed  CAS  Google Scholar 

  85. Ferrara T, Hoekstra R, Couser R, et al. Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J Pediatr 1994: 124: 119–24

    Article  PubMed  CAS  Google Scholar 

  86. Walti H, Polla BS, Bachelet M. Modified natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by resting and stimulating human monocytes. Pediatr Res 1997: 41: 114–9

    Article  PubMed  CAS  Google Scholar 

  87. Thomassen M, Antal J, Connors M, et al. Characterization of Exosurf (surfactant)-mediated suppression of stimulated alveolar macrophage cytokine responses. Am Respir Cell Mol Biol 1994: 10: 3999–404

    Google Scholar 

  88. Schrod L, Hornemann F, Von Stockhausen H. Chemilumines-cence activity of phagocytes from tracheal aspirates of premature infants after surfactant therapy. Acta Paediatr 1996; 85: 719–23

    Article  PubMed  CAS  Google Scholar 

  89. Tegtmeyer F, Möller J, Richter A, et al. Plasma concentration of elastase-alpha-proteinase inhibitor complex in surfactant treated preterm neonates with respiratory distress syndrome. Eur Repir J 1994; 7: 260–4

    Article  CAS  Google Scholar 

  90. Walti H, Fahrat M, Desfreres L, et al. Natural exogenous surfactant stimulates the acute phase reaction in premature neonates [abstract]. Pediatr Res 1996; 39: 355A

    Article  Google Scholar 

  91. Strayer D, Hallman M, Merritt T. Immunogenicity of surfactant. II: porcine and bovine surfactant. Clin Exp Immunol 1991; 83: 41–6

    Article  PubMed  CAS  Google Scholar 

  92. Strayer D, Hallman M, Merritt T. Immunogenicity of surfactant. I: human alveolar surfactant. Clin Exp Immunol 1991; 83: 35–40

    Article  PubMed  CAS  Google Scholar 

  93. Strayer D, Merritt T, Lwebuga-Musaka J, et al. Surfactant anti-surfactant immune complexes in neonatal respiratory distress syndrome. Am J Pathol 1986; 122: 353–2

    PubMed  CAS  Google Scholar 

  94. Chida S, Phelps D, Sool R, et al. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 1991; 88: 84–9

    PubMed  CAS  Google Scholar 

  95. Whitsett J, Hull W, Luse S. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics 1991; 87: 505–10

    PubMed  CAS  Google Scholar 

  96. Noack G, Berggren P, Curstedt T, et al. Severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant. Acta Paediatr Scand 1987; 76: 697–705

    Article  PubMed  CAS  Google Scholar 

  97. Bartmann P, Bamberger U, Pohlandt F, et al. Immunogenicity and immunomodulatory activity of bovine surfactant (SF-RI 1). Acta Paediatr 1992; 81: 383–8

    Article  PubMed  CAS  Google Scholar 

  98. Richman P, Spragg R, Asser S, et al. Comparison of the safety of three surfactant preparations for human use [abstract]. Pediatr Res 1987; 21: 464A

    Google Scholar 

  99. Strayer D, Merritt T, Hallman M. Levels of SP-A-anti-SP-A immune complexes in neonatal respiratory distress syndrome correlate with subsequent development of bronchopulmonary dysplasia. Acta Paediatr 1995; 84: 128–31

    Article  PubMed  CAS  Google Scholar 

  100. Moya F, Hoffman D, Zhao B, et al. Platelet activating factor in surfactant preparations. Lancet 1993; 241: 858–9

    Google Scholar 

  101. Enhörning G, Robertson B. Lung expansion in the premature fetus after tracheal deposition of surfactant. Pediatrics 1972; 50: 58–60

    PubMed  Google Scholar 

  102. Robertson B. Animal models of neonatal surfactant dysfunction. In: Robertson B, Van Golde LMG, Battenburg JJ, editors. Pulmonary surfactant: from molecular biology to clinical practice. Amsterdam: Elsevier, 1992: 459–84

    Google Scholar 

  103. Morley C. Systematic review of prophylactic vs rescue surfactant preparations. Lancet 1993; 241: 858–9

    Google Scholar 

  104. Dunn MS, Shennan AT, Zayack D, et al. Bovine surfactant replacement therapy in neonates of less than 30 weeks’ gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 1991; 87: 377–86

    PubMed  CAS  Google Scholar 

  105. Kendig JW, Notter RH, Cox C, et al. Comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 week gestation. N Engl J Med 1991; 324: 865–71

    Article  PubMed  CAS  Google Scholar 

  106. Egberts J, De Winter JP, Sedin G, et al. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks’ gestation: a randomized trial. Pediatrics 1993; 92: 1–7

    Google Scholar 

  107. Kattwinkel J, Bloom BT, Delmore P, et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks’ gestation. Pediatrics 1993; 92: 90–8

    PubMed  CAS  Google Scholar 

  108. Walti H, Paris-Llado J, Bréart G, et al. Porcine surfactant replacement therapy in newborns of 25–31 weeks’ gestation: a randomised multicentre trial of prophylaxis versus rescue with multiple low doses. Acta Paediatr 1995; 84: 913–21

    Article  PubMed  CAS  Google Scholar 

  109. Bevilacqua G, Parmingiani S, Robertson B, et al. Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomised trial. J Perinat Med 1996; 24: 1–12

    Article  Google Scholar 

  110. Walti H, Llado J, Bréart G, et al. Prophylactic administration of natural porcine surfactant (NPS) is a significant factor in reducing the odds for pen-intraventricular hemorrhage (PIVH) [abstract]. Pediatr Res 1997; 41: 186A

    Article  Google Scholar 

  111. Egberts J, Brand R, Walti H, et al. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after the prophylactic than after the therapeutic administration of the surfactant curosurf. Pediatrics 1997; 100: e4

    Article  PubMed  CAS  Google Scholar 

  112. Bevilacqua G, Halliday H, Parmigiani S, et al. Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress. J Perinat Med 1993; 21: 329–40

    Article  PubMed  CAS  Google Scholar 

  113. Konishi M, Fujiwara T, Naito T, et al. Surfactant replacement therapy in neonatal respiratory distress syndrome. Eur J Pediatr 1988; 147: 20–5

    Article  PubMed  CAS  Google Scholar 

  114. Dunn M, Shennan A, Possmayer F. Single versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks’ gestation with respiratory distress syndrome. Pediatrics 1990; 86: 564–71

    PubMed  CAS  Google Scholar 

  115. Speer CP, Robertson B, Curstedt T, et al. Randomized european multicenter trial of surfactant replacement therapy for severe neonates respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 1992; 89: 13–20

    PubMed  CAS  Google Scholar 

  116. Halliday H. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996; 51: 226–37

    Article  PubMed  CAS  Google Scholar 

  117. Soll R. Natural surfactant extract vs synthetic surfactant in the treatment of established respiratory distress syndrome. In: Sinclair J, Bracken M, Soll R, et al., editors. Neonatal module of the Cochrane database of systematic reviews [Available in: the Cochrane Library (database on disk or CD Rom)]. The Cochrane collaboration. Issue 4. Oxford: Update Software, 1997

  118. Pearlman S, Leef K, Stefano J, et al. A randomized trial comparing Exosurf VS. Survanta in the treatment of neonatal RDS [abstract]. Pediatr Res 1993; 33: 340; 2017

    Google Scholar 

  119. Vermont-Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996; 97: 1–6

    Google Scholar 

  120. Modalou H, Beharry K, Norris K, et al. Comparative effects of Survanta (Surv) and Exosurf (Exo) on the outcome of respiratory distress syndrome (RDS) [abstract]. Pediatr Res 1994; 35: 242: 1436

    Google Scholar 

  121. Alvarado M, Hingre R, Hakanson D, et al. Clinical trial of Survanta VS Exosurf therapy in infants < 1500g with respiratory distress syndrome (RDS) [abstract]. Pediatr Res 1993; 33: 314; 1865

    Google Scholar 

  122. Seghal S, Ewing C, Richards T, et al. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 1994; 84: 46–52

    Google Scholar 

  123. Hudak M, Martin D, Egan E, et al. A multicenter randomized trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997; 100: 39–50

    Article  PubMed  CAS  Google Scholar 

  124. Hall S, Venkitaraman A, Whitsett J, et al. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactant. Am Rev Respir Dis 1992; 145: 24–30

    Article  PubMed  CAS  Google Scholar 

  125. Mizumo K, Ikegami M, Chen C, et al. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res 1995; 37: 271–6

    Article  Google Scholar 

  126. Speer C, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 1995; 72: F8–13

    CAS  Google Scholar 

  127. Bloom B, Kattwinkel J, Hall R, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997; 100: 31–8

    Article  PubMed  CAS  Google Scholar 

  128. Maniscalco W, Kendig J, Shapiro D. Surfactant replacement therapy: impact on hospital charges for premature infants with respiratory distress syndrome. Pediatrics 1989; 83: 1–6

    PubMed  CAS  Google Scholar 

  129. Mugford M, Piercy J, Chalmers I. Cost implication of different approaches to the prevention of respiratory distress syndrome. Arch Dis Child 1991; 66: 757–64

    Article  PubMed  CAS  Google Scholar 

  130. Phibbs C, Phills R, Wakeley A, et al. Cost effects of surfactant therapy for neonatal respiratory distress syndrome. J Pediatr 1993; 123: 953–62

    Article  PubMed  CAS  Google Scholar 

  131. Bryson H, Whittington R. Colfosceril palmitate: a pharmaco-economic evaluation of a synthetic surfactant preparation (Exosurf® Neonatal ™) in infants with respiratory distress syndrome. Pharmacoeconomics 1994; 6: 564–77

    Article  Google Scholar 

  132. Schwartz R, Luby A, Scanlon J, et al. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500g. N Engl J Med 1994; 330: 1476–80

    Article  PubMed  CAS  Google Scholar 

  133. Eidelman A. Economic consequences of surfactant therapy. J Perinatol 1993; 13: 137–9

    PubMed  CAS  Google Scholar 

  134. Tubmann T, Halliday H, Normand C. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. BMJ 1990; 301: 842–5

    Article  Google Scholar 

  135. Hörbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics 1993; 92: 191–6

    PubMed  Google Scholar 

  136. Zola E, Overbach A, Gunkel H, et al. Treatment investigational drug experience with survanta (beractant). Pediatrics 1993; 91: 546–51

    PubMed  CAS  Google Scholar 

  137. Walti H, Claris O, Lacaze-Masmonteil T, et al. Prospective longitudinal study of 1154 babies treated with natural porcine surfactant (NPS) [abstract]. Pediatr Res 1997; 41: 213A

    Article  Google Scholar 

  138. Formally S, Clarke T, Krishman A, et al. Surfactant therapy in respiratory distress syndrome: the effect of a learning curve. Ir J Med Sci 1993; 162: 458–61

    Article  Google Scholar 

  139. Kari M, Hallman M, Eronen M, et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics 1994; 93: 730–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Médecine Néonatale, Hôpital Cochin-Port-Royal, 123, Bld de Port-Royal, 75679, Paris Cedex 14, France

    Hervé Walti & Michèle Monset-Couchard

Authors
  1. Hervé Walti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michèle Monset-Couchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hervé Walti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walti, H., Monset-Couchard, M. A Risk-Benefit Assessment of Natural and Synthetic Exogenous Surfactants in the Management of Neonatal Respiratory Distress Syndrome. Drug-Safety 18, 321–337 (1998). https://doi.org/10.2165/00002018-199818050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199818050-00002

Keywords

Search

Navigation